Cooperative Agreement U18DA052537

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of a novel CB1 antagonist, ANEB-001, for the treatment of acute cannabinoid intoxication (ACI) and cannabis hyperemesis syndrome (CHS). The project, with a total funding of $892,290.00 over 2 years, will investigate the safety, pharmacokinetics, and therapeutic potential of an intravenous formulation of ANEB-001 in...

Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...

This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of FGF13-NAV1.6 modulators to normalize nucleus accumbens activity for the treatment of Cocaine Use Disorder (CUD). The project will conduct structure-activity relationship (SAR) analysis and optimization of the lead compound 5788 (Aim 1), followed by pharmacokinetic (PK) studies of 5788 analogues (Aim 2) and in vivo efficacy...

This federal Project Grant award of $421,200.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the development of chemical biology tools to study the interactions between cannabinoid and opioid signaling pathways in the brain. The objective is to expand the researchers' existing toolkit of fluorescent probes and photoswitches to target the atypical cannabinoid receptor GPR55, and apply these tools to investigate the role of cannabinoid...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $2,118,992 to the University of Miami to conduct research on the neural and psychiatric consequences of cannabis use in adolescents. The research will prospectively investigate the effects of cannabis, the most widely used illicit drug among teenagers, on reward and pain neurocircuits in adolescents with depression. The study aims to understand...

This Project Grant award, valued at $376,078.00 and funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to explore the antecedents and consequences of cannabis use for coping purposes. The study will experimentally test whether cannabis use quantity increases after a stress induction among individuals who use cannabis to cope, as well as examine factors that may moderate this effect, such as social anxiety...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a 5-year, $2,726,432 research study on the co-use of cannabis and prescription opioids among emerging adults in medical settings. The study will enroll emerging adults ages 18-25 who are prescribed opioids for acute pain management, with the majority having used cannabis in the past month. The research aims to examine how pain experiences,...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,875 to the University of California, Los Angeles (UCLA) to conduct a randomized, double-blind, crossover human laboratory study on the use of delta-9-tetrahydrocannabivarin (D9-THCV) as a potential treatment for nicotine dependence and smoking cessation. The study will enroll 32 daily smokers to assess the ability of D9-THCV to: (a)...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $675,107 to Northeastern University to conduct research aimed at developing non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize novel cannabinoid receptor (CB1R and CB2R) agonist-positive allosteric...